ClinicalTrials.gg
RecruitingNCT07400367Updated Apr 6, 2026

Impact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

An interventional study of Probiotic product and Life style modification in Liver Elastography, Liver Steatosis and Liver Function Test, sponsored by Fu Jen Catholic University Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Fu Jen Catholic University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Fatty Liver with a site in Taiwan — 8 open to participants now, 10 under way, 5 of them phase 3. Fatty Liver · Taiwan.

Planned enrollment
10th of 15
80 · median 100
Started
2026
the only one that year
No phase
6 of 20
3 open now
Registered
18th of 20
by date
Lead sponsor
1 of 20
Fu Jen Catholic University Hospital

Among the 20 studies in Fatty Liver with a site in Taiwan, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 18th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

8 of the 20 studies in Fatty Liver with a site in Taiwan are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Fatty Liver with a site in Taiwan, or all of them as a file.
02

Study summary

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the new clinical term introduced in 2023 to redefine what was formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD). It is defined as fatty liver confirmed by imaging or biopsy, accompanied by at least one cardiometabolic risk factor (e.g., hyperglycemia, dyslipidemia, hypertension, or obesity). Its pathological progression ranges from simple steatosis to steatohepatitis, primarily driven by excessive energy intake, hepatic lipid accumulation, and insulin resistance.

MASLD is currently the most prevalent chronic liver disease globally, with a prevalence rate of approximately 30-40%. However, there is no satisfactory pharmacological treatment, leaving lifestyle modification as the primary therapeutic approach. Many patients struggle to effectively adjust their habits, leading to persistent hepatic inflammation and damage, which may eventually progress to end-stage diseases such as cirrhosis and hepatocellular carcinoma. In many developed countries, MASLD has become the leading indication for liver transplantation, imposing a heavy burden on healthcare systems.

Gut dysbiosis is closely linked to MASLD. An imbalance in the gut microbiota disrupts the gut-liver axis, leading to impaired intestinal mucosal barrier function. This allows bacterial components to enter the circulation, further triggering hepatic inflammation and abnormal lipid metabolism. Consequently, modulating the gut microbiota is considered a potential therapeutic strategy.

Over the past decade, probiotics, prebiotics, and synbiotics have been extensively studied as non-pharmacological treatments for NAFLD. Multiple studies indicate that these products can reduce liver enzymes (AST, ALT), insulin resistance (HOMA-IR), and inflammatory markers (hs-CRP, TNF-α). The most effective combinations typically involve Lactobacillus, Bifidobacterium, and Streptococcus, with a recommended duration of approximately 12 weeks. However, the impact of these products on liver fibrosis, hepatic fat accumulation, and cardiometabolic risk factors remains inconclusive.

The probiotic product to be tested consists of Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, Bifidobacterium animalis CP-9, and Lactobacillus reuteri GL-104. This formulation complies with food safety regulations. In clinical studies, it had been proven as an effective adjuvant method that increased beneficial gut bacteria such as Akkermansia muciniphila and improved the control of blood glucose, lipids, and inflammatory markers.

Study Objectives

This study aims to investigate the efficacy of this probiotic product as an adjuvant therapy alongside lifestyle modifications in adult patients with MASLD. We will evaluate its impact on:

  1. The degree of liver fibrosis and steatosis
  2. Cardiometabolic risk factors (BMI, waist circumference, blood lipids, and blood glucose).
  3. Inflammatory markers.
  4. Gut microbiota composition.
03

Conditions studied

  • Liver Elastography
  • Liver Steatosis
  • Liver Function Test
  • Insulin Resistance
  • Cardiometabolic Risk Factors

Keywords

  • MASLD
  • Probiotics
  • Liver fibrosis
  • Liver steatosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 60 U/L
  • Liver steatosis identified by ultrasound
  • Meet at least one cardiometabolic criteria:

    1. ≥ 25 kg/m2 (Asian ≥23)
    2. Waist circumference: > 94cm (M) 80cm(F)
    3. Fasting blood glucose ≥ 100 mg/dL
    4. ≥ 5.7
    5. Receiving treatment of diabetes
    6. Receiving treatment of Hypertension
    7. Average home blood pressure: ≥ 130/85 mmHg
    8. TG ≥ 150 mg/dL
    9. HDL ≤ 40 mg/dL
    10. Receiving treatment of dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • (+)
  • Anti- (+)
  • Cirrhosis
  • Excessive alcohol intake ( Male over 210g/wk; Female over 140mg/wk)
  • Could not rule out hepatitis (ANA, or AMA or ASMA (+))
  • Could not rule out drug related hepatitis
  • Receiving drug that might induce liver steatosis:
  • Amiodarone
  • Tamoxifen
  • Methotrexate
  • Valproate
  • Tetracycline
  • Chemotherapeutic agents
  • Receiving immune modulators or biologics
  • Receiving antibiotics within 1 month
  • Receiving any cancer treatment
  • Have diagnosis of "Catastrophic Illness" defined by Health Administration of Taiwan
  • \<60
  • Pregnancy
  • Currently enrolled in other dietary or pharmacology clinical trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention

    Receive the probiotic product one sachet per day and standard lifestyle modification education for MASLD by a gastroenterologist.

    Dietary Supplement: Probiotic product · Behavioral: Life style modification

  • Active comparator
    Placebo

    Receive the placebo one sachet per day and standard lifestyle modification education for MASLD by a gastroenterologist.

    Behavioral: Life style modification · Dietary Supplement: placebo

Interventions

  • Dietary supplementProbioticStudies of ProbioticProbiotic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The probiotic product contains Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, Bifidobacterium animalis CP-9 and Lactobacillus reuteri GL-104

  • BehavioralLife style modification

    Life style modification of MASLD provided by an gastroenterologist in an outpatient s

  • Dietary supplementplacebo

    placebo sachet looked and taste very similar to the probiotic product being tested

06

What researchers measure

Primary outcomes

  1. Change in shear wave elastography (m/s) at 12 weeks

    Change in liver fibrosis at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Change in ultrasound attenuation coefficient (dB/cm/MHz) at 12 weeks

    Change in liver steatosis at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Change in blood LDL level (mg/dL) at 12 weeks

    Change in blood LDL level (mg/dL) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Change in blood HDL level (mg/dL) at 12 weeks

    Change in blood HDL level (mg/dL) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Change in blood total cholesterol level (mg/dL) at 12 weeks

    Change in blood total cholesterol level (mg/dL) at 12 weeks

    Time frame: Time Frame: From enrollment to the end of treatment at 12 weeks

  5. Change in blood triglycerides level (mg/dL) at 12 weeks

    Change in blood triglycerides level (mg/dL) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  6. Change in HOMA-IR at 12 weeks

    Change in insulin resistance at 12 week

    Time frame: From enrollment to the end of treatment at 12 weeks

  7. Change in blood fasting insulin level (μU/mL) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  8. Change in blood fasting glucose level (mg/dL) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  9. Change in blood AST level (U/L) at 12 weeks

    Change in liver function test

    Time frame: From enrollment to the end of treatment at 12 weeks

  10. Change in blood ALT level (U/L) at 12 weeks

    Change in liver function test

    Time frame: From enrollment to the end of treatment at 12 weeks

  11. Change in blood gamma-GT level (U/L) at 12 weeks

    Change in liver function tests

    Time frame: From enrollment to the end of treatment at 12 weeks

  12. Change in blood alkaline phosphatase level (IU/L) at 12 weeks

    Change in liver function tests

    Time frame: From enrollment to the end of treatment at 12 weeks

  13. Change in blood BUN level (mg/dL) at 12 weeks

    Change in renal function

    Time frame: From enrollment to the end of treatment at 12 weeks

  14. Change in blood Creatinine level (mg/dL) at 12 weeks

    Change in renal functions

    Time frame: From enrollment to the end of treatment at 12 weeks

  15. Change in eGFR level (mL/min/1.73m^2) at 12 weeks

    Change in renal function

    Time frame: From enrollment to the end of treatment at 12 weeks

  16. Change in blood albumin level (g/dL) at 12 weeks

    Change in liver functions at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  17. Change in platelet level (*10^3/uL) at 12 weeks

    For the calculation of the chane of Fib-4 score at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  18. Change in HbA1c level (%) at 12 weeks

    Change in blood sugar control at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  19. Change in blood hs-CRP level (mg/L) at 12 weeks

    Change in systemic inflammation at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  20. Change in blood IL-6 level (pg/mL) at 12 weeks

    Change in systemic inflammation at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  21. Change in blood TNF-alpha level (pg/mL) at 12 weeks

    Change in systemic inflammation at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  22. Change in Fib-4 score at 12 weeks

    Change in liver fibrosis score at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  23. Change in ARPI score at 12 weeks

    Change in liver fibrosis score at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  24. Change in NAFLD Fibrosis Score at 12 weeks

    Change in liver fibrosis score at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  25. Change in blood pressures (mmHg) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  26. Change in body weight (kg) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  27. Change in BMI (kg/m^2) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

  28. Change in waist circumference (cm) at 12 weeks

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN. 2020 Oct;39:53-60. doi: 10.1016/j.clnesp.2020.06.020. Epub 2020 Jul 24. PubMed 32859329 ↗
  • Inoue K, Tsukuda S, Kayano H, Tanaka J, Heshiki A. A case of hypervascular renal capsule leiomyoma. Radiat Med. 2000 Sep-Oct;18(5):323-6. PubMed 11128405 ↗
  • Kumada T, Toyoda H, Ogawa S, Gotoh T, Yoshida Y, Yamahira M, Hirooka M, Koizumi Y, Hiasa Y, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Tanaka J, Shimizu M. Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study. Hepatol Res. 2024 Sep;54(9):851-858. doi: 10.1111/hepr.14026. Epub 2024 Feb 13. PubMed 38349813 ↗
  • Farrow A, Farrow SC, Little R, Golding J. The repeatability of self-reported exposure after miscarriage. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Int J Epidemiol. 1996 Aug;25(4):797-806. doi: 10.1093/ije/25.4.797. PubMed 8921459 ↗
  • Jansson JH, Boman K, Brannstrom M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. Circulation. 1997 Nov 4;96(9):2938-43. doi: 10.1161/01.cir.96.9.2938. PubMed 9386160 ↗
  • Yang Y, Yang L, Wu J, Hu J, Wan M, Bie J, Li J, Pan D, Sun G, Yang C. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis. Clin Nutr. 2024 Jun;43(6):1224-1239. doi: 10.1016/j.clnu.2024.04.004. Epub 2024 Apr 13. PubMed 38643738 ↗
  • Wu J, Chen X, Qian J, Li G. Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2024 Aug;48(7):102397. doi: 10.1016/j.clinre.2024.102397. Epub 2024 Jun 13. PubMed 38879003 ↗
  • Sharma S, Tiwari N, Tanwar SS. The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis. Naunyn Schmiedebergs Arch Pharmacol. 2025 Sep;398(9):11541-11579. doi: 10.1007/s00210-025-04069-z. Epub 2025 Apr 9. PubMed 40202676 ↗
  • Ledru E, Diagbouga S, Tranchot-Diallo J, Cauchoix B, Yameogo M, Chami D, Soula G, Chiron JP. Eosinophils: a putative marker of immunodepression in HIV-infected African patients with tuberculosis? Trans R Soc Trop Med Hyg. 1994 Jan-Feb;88(1):117-8. doi: 10.1016/0035-9203(94)90531-2. No abstract available. PubMed 7908766 ↗
  • Su X, Chen S, Liu J, Feng Y, Han E, Hao X, Liao M, Cai J, Zhang S, Niu J, He S, Huang S, Lo K, Zeng F. Composition of gut microbiota and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Obes Rev. 2024 Jan;25(1):e13646. doi: 10.1111/obr.13646. Epub 2023 Oct 9. PubMed 37813400 ↗

Individual participant data

Plan to share: Yes — de-identification data

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 13 months is below that.

Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 10, 2026
StartActual
Apr 1, 2026
Primary completionEst.
May 2027
CompletionEst.
Aug 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07400367
Lead sponsor
Fu Jen Catholic University Hospital
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Apr 1, 2026
Primary completion
May 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Kuan Wei Wu
Contact
david800413@gmail.com
+886-922-710-756

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion